Peripheral Neuropathy and Cardiac Autonomic Neuropathy among Type II Diabetic Patients: Prevalence and Risk Factors

B. V. Surendra1, N. S. Muthiah2, M. V. Sailaja3,4 and K. Sreenivasulu4

1Department of Physiology, Bharath Institute of Higher Education and Research, Chennai, India. 2Department of Pharmacology, Balaji Medical College, Chennai, India. 3Department of Physiology, Viswabharathi Medical College, Kurnool, India. 4Department of Anatomy, Viswabharathi Medical College, Kurnool, India.

Authors’ contributions
This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i39B32186
Editors:
(1) Dr. Rafik Karaman, Al-Quds University, Palestine.
(2) Myrna Buenaluz Sedurante, University of the Philippines, Philippines.
(2) Razaw O.Ibrahim, University of Kirkuk, Iraq.
Complete Peer review History: https://www.sdiarticle4.com/review-history/71802

Received 24 May 2021
Accepted 28 July 2021
Published 02 August 2021

ABSTRACT

Background: The two most common chronic complication softype 2 diabetes mellitus (T2DM) are peripheral neuropathy (PN) and Cardiac autonomic neuropathy (CAN). Diagnosing neuropathies at subclinical stage can prevent the morbidity and mortality.

Objectives: To determine the prevalence of peripheral neuropathy and cardiovascular autonomic neuropathy and their risk factors in type-II diabetic patients attending a tertiary care hospital.

Methods: An observational cross-sectional study was done from December 2019 to November 2020 in the department of General medicine at tertiary care hospital. 273 type II diabetic patients were selected for this study. Toronto clinical scoring system was used for assessing PN and ewings cardiovascular reflex study was used done to assess CAN. To identify the risk factors of PN and CAN, Logistic regression analysis was used.

Results: The prevalence of PN and CAN was 45.4% and 34.06% respectively, while 29.3% participants had both. Smoking (OR: 12.976; 95% CI: 0.052–0.418, P<0.0001) and poor glycaemic control (OR: 27.231; 95% CI: 5.226–38.201, P<0.0001) were independent risk factors of DPN.
poorglycaemic control (OR: 26.970; 95% CI: 3.507 – 16.055, P <0.0001) and Dyslipidimea (OR: 11.792; 95% CI: 0.096 – 0.526, P ≤ 0.001) were independent predictors of CAN.

Interpretation and Conclusions: PN and CAN are common among diabetic patients, and thus it is recommended to screen Peripheral Neuropathy and CAN in all diabetic patients for the early diagnosis and preventing the debilitating complications.

Keywords: Type-II diabetes mellitus; peripheral neuropathy; cardiac autonomic neuropathy (CAN); toronto clinical scoring system (TCSS); ewings tes.

1. INTRODUCTION

Diabetic Neuropathy (DN) is the major cause for hospitalization than other complications of diabetes and is also the most common cause for non-traumatic amputation and autonomic failure [1,2] and thus causing negative effect significantly on quality of life of patients with T2DM [3].

There are 4 different types of neuropathy: peripheral neuropathy, proximal neuropathy, autonomic neuropathy & focal neuropathy. In peripheral neuropathy the symptoms varies from severely painful at one extreme to the completely painless and the patients having damage to the nerves loses the ability to perceive the sensations like heat, cold and pain in extremities and thus Peripheral Neuropathy participates in causing foot ulceration [4].

In CAN, parasympathetic and sympathetic functions are altered, but still these dysfunctions are masked for longtime. CAN is identified at later stages as autonomic system can react to both internal environment stress and external environment stress [5]. CAN is one of the leading cause of increasing incidence of silent myocardial ischemia and sudden death is in T2DM patients [6-7].

Early screening, appropriate intervention and treatment of Peripheral neuropathy and CAN in T2DM are very important as these two neuropathies are masked and neglected at subclinical stage and ultimately leading to debilitating complications.

The present study was planned to determine the prevalence and risk factors of peripheral neuropathy, Cardiac autonomic neuropathy (CAN) among type-II Diabetes Mellitus participants in a tertiary care hospital.

2. MATERIALS AND METHODS

This cross sectional observational study was done among type II Diabetic patients attending general medicine OPD at Viswabharathi medical college Kurnool from December 2019 to November 2020.

Sample size estimation: A sample size of 273 was calculated based on the prevalence of diabetic neuropathy to be 19% from a study done by Ashok S et al. [8] in South India with an absolute precision of 5% and 10% non-response rate using the formula 4pq/d2.

The Inclusion criteria are Type II Diabetes mellitus patients aged 35 to 80 years & with ≥ 3 years of duration of diabetes.

The Exclusion criteria are Other known causes of peripheral neuropathy, history of patients related to nerve injury, pregnant woman who had gestational diabetes, presence of foot ulcers & amputations, Participants with other diseases associated with autonomic nervous system dysfunction, Patients on drugs like antiarrhythmics, patients with underlying cardiac illness like coronary artery disease, ischemic heart disease, rheumatic heart disease, and cardiac failure,

Sampling technique: Purposive sampling method

All the patients underwent a standardized clinical evaluation

Study protocol: Demographic data such as age, sex, Smoking & hypertension history by using structured questionnaire

BMI: Participants height and weight were measured and Body mass index (BMI) was calculated

Hypertension: blood pressure of the participants was measured in the right arm using mercury column sphygmomanometer after patient had adequately rest and seated and considered to be hypertensive if SBP ≥140 mm Hg or DBP ≥ 90 mm Hg or taking anti hypertensive drugs [9].
**Biochemical analysis:** Five milliliters of venous bloods was drawn under aseptic conditions for serum glycosylated haemoglobin (HB), serum triglycerides & Cholesterol.

Serum total cholesterol and triglycerides was investigated by enzymatic (CHOD-PAP) colorimetric method [10] and enzymatic (GPO-PAP) method [11] on Stat Fax 3300 semi auto analyzer. Dyslipidemia was considered if total cholesterol was ≥ 200 mg/dl and total triglycerides ≥ 150 mg/dl [12]. By Immuno turbidimetric latex method [13] HbA1c was investigated on Robonik Prietest semi analyser.

**Diabetic peripheral neuropathy:** TCSS Scale was used for screening DPN among type-II diabetic patients. Scoring was given for symptoms, sensory tests & reflexes. Based on the abnormalities, for symptoms and sensory tests, a point of 0 or 1 was given and for reflexes a point of 0, 1 or 2 was given. Total score ranges from 0 to 19. Finally, for Symptoms 6 points were given, for sensory examination 5 points were given and for lower limb reflexes, 8 points were given. Components of the scale are:

- Foot symptoms scores: Pain, Numbness, Tingling, Weakness and Ataxia.
- Upper-limb symptoms, sensory testing: Pinprick, Temperature, Light touch, Vibration and Position.
- Reflexes: Knee reflexes and Ankle reflexes

Severity of neuropathy was classified based on the score as: Score of 0-5= no peripheral neuropathy; 6-8= mild PN; 9-11= moderate PN; 12-19= severe [14].

**Ewings Cardiovascular Reflex Tests (CRT):**
All the patients selected for study underwent Cardiovascular Reflex Tests (CRT) for evaluation of Cardiac autonomic neuropathy. Standard 12 lead ECG was taken and heart rate was measured by continuous ECG recording using lead II. All five Ewing’s tests [15] were performed as following for the detection of DCAN (diabetic cardiac autonomic neuropathy).

**Instruments:**
1. ECG instrument (CONTEC ECG300G) with paper speed of 25mm/sec
2. Diamond Sphygmomanometer BP instrument

**I. Tests for assessing parasympathetic function:**
1) Heart rate response to deep breathing test:
2) Heart rate response to Valsalva maneuver
3) Heart rate response to standing

**II. Tests for assessing sympathetic function:**
1) Blood pressure response to sustained hand grip
2) Blood pressure response to standing

The results were then categorized into one of the four groups:
- Normal
- Early CAN - One of three parasympathetic tests abnormal or two borderline
- Definite CAN- Two parasympathetic tests abnormal
- Severe CAN- Two parasympathetic tests abnormal + one or both sympathetic tests abnormal

**Statistics**
Data analysis was done by using SPSS-16. continuous variables were reported as mean ± standard deviation and categorical variables were reported as percentages. Risk factors associated with DPN and CAN were determined using multivariate logistic regression analyses, with results presented as adjusted odds ratio (OR) with corresponding 95% confidence interval (CI). The accepted level of significance was set below 0.05 (P<0.05).

3. RESULTS
The characteristics of the study participants were described in Table 1.

The tests of diabetic peripheral neuropathy and cardiac autonomic neuropathy were described in Table 2.

Factors associated with Diabetic peripheral Neuropathy on multivariate analysis were described in Table 3.

Factors associated with cardiac autonomic neuropathy on multivariate analysis were described in Table 4.

4. DISCUSSION
This study estimated the prevalence and risk factors of peripheral neuropathy and CAN among type II diabetic patients attending a tertiary care
### Table 1. Characteristics of study subjects

| Baseline characteristics | Mean±SD | Category | Frequency (n) | Percentage (%) |
|--------------------------|---------|----------|---------------|----------------|
| Sex                      | -       | Male     | 142           | 52             |
|                          |         | female   | 131           | 48             |
| Age                      | 54.75±9.65 | -       | -             | -              |
| Duration of DM (Years)   | 7.41±3.38 | -       | -             | -              |
| BMI (kg/m²)              | 25.42±4.05 | -       | -             | -              |
| SBP                      | 129.70±16.68 | -     | -             | -              |
| DBP                      | 81.91±9.98  | -       | -             | -              |
| HbA1c(%)                 | 6.12±0.57  | -       | -             | -              |
| Serum Cholesterol (mg/dl)| 186.71±38.85 | -  | -             | -              |
| Serum Triglycerides (mg/dl)| 136.68±22.58 | -  | -             | -              |
| Hypertension             | -       | absent   | 162           | 59             |
|                          |         | present   | 111           | 41             |
| Dyslipidemia             | -       | absent   | 179           | 65             |
|                          |         | present   | 94            | 34             |
| smoking                  | -       | absent   | 197           | 72             |
|                          |         | present   | 76            | 28             |

### Table 2. Tests of diabetic peripheral neuropathy and cardiac autonomic neuropathy

| 9.5                  | Participants (n=273), n(%) |
|----------------------|---------------------------|
| DPN                  |                           |
| Present              | 124 (45.4)                |
| Absent               | 149 (54.6)                |
| Valsalva             |                           |
| Abnormal 27 (9.9)    |                           |
| Borderline           | 82 (30.0)                 |
| Normal               | 164 (60.1)                |
| Deep breathing       |                           |
| Abnormal             | 58 (21.2)                 |
| Borderline           | 24 (8.8)                  |
| Normal               | 191 (70.0)                |
| HRV to standing      |                           |
| Abnormal             | 46 (16.9)                 |
| Borderline           | 45 (16.5)                 |
| Normal               | 182 (66.6)                |
| BP change on standing|                           |
| Abnormal             | 05 (1.8)                  |
| Borderline           | 05 (1.8)                  |
| Normal               | 263 (96.4)                |
| BP change on handgrip|                           |
| Abnormal             | 2 (0.7)                   |
| Borderline           | 7 (2.6)                   |
| Normal               | 264 (96.7)                |
| CAN                  |                           |
| Present              | 93 (34.0)                 |
| Absent               | 180 (66.0)                |
| Type of can          |                           |
| Early                | 36 (38.7)                 |
| Definite             | 51 (54.8)                 |
| Advance              | 6 (6.5)                   |
| DPN + CAN            |                           |
| Present              | 80 (29.3)                 |
| Absent               | 193 (70.7)                |

BP: Blood pressure, HRV: Heart rate variability DPN: Diabetic Peripheral Neuropathy, CAN: Cardiovascular autonomic neuropathy
Table 3. Factors associated with Diabetic peripheral Neuropathy on multivariate analysis

| Variables                          | OR     | 95% CI Lower | 95% CI Upper | p   |
|------------------------------------|--------|--------------|--------------|-----|
| Age ≥60 years                      | 1.638  | 0.062        | 1.795        | 0.201 |
| Male sex                           | 3.163  | 0.075        | 1.078        | 0.957 |
| Duration of diabetes ≥8 years      | 0.003  | 0.354        | 2.995        | 3.043 |
| Presence of hypertension           | 1.039  | 0.308        | 0.704        | 3.146 |
| BMI                                | 0.025  | 0.875        | 0.260        | 3.146 |
| Poor glycaemic control             | 27.231 | 5.226        | 38.201       | <0.001* |
| Smoking                            | 12.976 | 0.052        | 0.418        | <0.001* |
| Dyslipidemia                       | 0.949  | 0.265        | 1.563        | 0.330 |

Table 4. Factors associated with cardiac autonomic neuropathy on multivariate analysis

| Variables                          | OR     | 95% CI Lower | 95% CI Upper | p   |
|------------------------------------|--------|--------------|--------------|-----|
| Age ≥60 years                      | 0.097  | 0.281        | 5.751        | 0.755 |
| Male sex                           | 0.034  | 0.480        | 2.424        | 0.854 |
| Duration of diabetes ≥8 years      | 0.012  | 0.350        | 2.554        | 0.912 |
| Presence of hypertension           | 1.235  | 0.726        | 3.187        | 0.266 |
| BMI                                | 0.020  | 0.361        | 3.247        | 0.887 |
| Poor glycaemic control             | 26.970 | 3.507        | 16.055       | <0.001* |
| Smoking                            | 0.115  | 0.314        | 2.264        | 0.735 |
| Dyslipidemia                       | 11.792 | 0.096        | 0.526        | 0.001* |

hospital in Kurnool. The prevalence of DPN as evaluated by TCSS in this study was 45%. Sankari Mansa Devi H et al. [16] in 2015 reported the prevalence of DPN among OPD attendants as evaluated by TCSS as 13.2%. Sangeetha et al. [17] in 2019 in their study reported the prevalence of DPN as evaluated by MNSI history version and MNSI examination as 31% & 24%.

Prevalence of CAN in this study was 34%. DAN study in 2014 reported the prevalence of CAN among the type-II Diabetes as 35% [18] & Lerner et al. [19] al in 2015 reported the prevalence of CAN as 37% among type II diabetic patients which are correlating to the present study. Tallat N et al. [20] in 2019 reported the prevalence of CAN as 40%. Gupta and Gupta in 2017 [21] reported prevalence of CAN as 54%.

The results of this study showed that the development of peripheral neuropathy had a significant association with poor glycaemic control. Similar observation was described in a study by Bansal et al. [22]. The result of this study showed that Habit of smoking increased the risk of DPN. Similar observation was described in a study by Katulanda P et al. [23].

This study did not find significant association peripheral neuropathy with age, sex, duration of diabetes, hypertension, BMI & dyslipidemia. Smoking [24–26] may increase the risk of nerve damage through oxidative stress, systemic inflammation, and endothelial dysfunction independent of diabetes [24–26], in parallel with metabolic factors.

The results of this study showed that the development of CAN had a significant association with poor glycaemic control. Similar observation was described in a study by Anjum S et al. [27]. The results of this study showed that the development of CAN had a significant association with dyslipidemia. Similar observation was described in a study by Zuern et al. [28].

This study did not find significant association of CAN with age, sex, duration of diabetes, hypertension, BMI & smoking. Even though in clinical trials the association of dyslipidemia with neuropathy is confirmed, the mechanism by which dyslipidemia causes neuropathy is not clear. Of these possibly the most important is,
oxidative stress. Increased oxidative stress can lead to the pathology of neural dysfunction in diabetes and has been proposed as a mechanism that contributes to the pathogenesis of neuropathy [29,30].

In our study it was observed that Patients with poor glycaemic control have about 27 times increase in the risk of developing PN& CAN. Blood glucose levels if consistently high, can lead to macrovascular and micro vascular complications which affect patients quality of life [31]. Hyperglycemia contributes to the activation of various biochemical pathways related to the metabolic state of the cell and along with impaired nerve perfusion, contributes to the development and progression of diabetic neuropathies [32].

5. CONCLUSION

This study showed that PN and CAN are quite common among diabetic patients and with about one in four patients having a mixed form of the two. In the regular examination of Type 2 Diabetes Mellitus patients, these simple noninvasive tests for Peripheral Neuropathy and Cardiac autonomic neuropathy can be incorporated for the early diagnosis of peripheral neuropathy and cardiac autonomic neuropathy to prevent the complications.

DISCLAIMER

The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

CONSENT AND ETHICAL APPROVAL

Institutional ethics committee approval was taken for conducting the study and written & informed consent form was taken from all the participants.

ACKNOWLEDGEMENTS

We, the authors sincerely thanks Dr. Sukumar, Dr. Prabhu, Paramedics & participants for their cooperation and contribution towards this study.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Feldman EL, Stevens MJ, Russell JW, Greene DA. Somatosensory neuropathy. In: Porte D, Sherwin RS, Baron A, editors. Ellenberg and Rifkin’s diabetes mellitus. McGraw Hill: New York, USA. 2002;771–88.

2. Vinik AI, et al. Diabetic autonomic neuropathy. In: Porte D, Sherwin RS, Baron A, editors. Ellenberg and Rifkin’s diabetes mellitus. 6 th ed. McGraw Hill: New York, USA. 2002;789–04.

3. Freeman R. The peripheral nervous system and diabetes. In:Weir G, Kahn R,King GL, edts. Joslin’s Diabetes Mellitus. Philadelphia: Lipincott; 2002.

4. American Diabetes Association. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care. 28:956–962.

5. JermendyG. Clinical consequences of cardiovascular autonomic neuropathy in diabetic patients. Acta Diabetol. 2003;40:(Suppl2):S370–4.

6. Veglio M, Borra M, Stevens LK, etal. The relation between QTc interval prolongation and diabetic complications. The EURODIAB IDDM Complication Study Group.Diabetologia.1999;42:68–75.

7. Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D; 2005.

8. Ashok S, Ramu M, Deepa R, Mohan V. Prevalence of neuropathy in type 2 diabetic patients attending a diabetes centre in South India. JAPI. 2002;50:546-50.

9. Chobanian AV, Bakris GL, Black HR, et al. “The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report,” e Journal of the American Medical Association. 2003;289(19):2560–2572.

10. Allain CC, Poon IS, Chan CHG, Richmond W, Fu PC. Enzymatic determination of
11. Jacobs NJ, Van Denmark PJ. Enzymatic determination of serum triglyceride. ch. Biochem. Biophys. 1960;88:250-255.

12. National cholesterol education program: Detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Circulation. 2002;106:3143-3421.

13. Engbaek F, Christensen SE, Jespersen B. Enzyme immunoassay of hemoglobin A1c: analytical characteristics and clinical performance for patients with diabetes mellitus, with and without uremia. Clin Chem. 1989;35(1):93-7.

14. Vera Bril, Bruce Perkins A. Validation of the Toronto clinical scoring system for diabetic polyneuropathy. Diabetes Care, 2002;25(11):2048-2052.

15. Ewing DJ, Martyn CN, Young RJ, Clarke BF. The value of cardiovascular autonomic function tests: 10 years experience in diabetes. Diabetes Care. 1985;8(5):491–498.

16. Sankari Mansa Devi H et al. Prevalence and determinants of peripheral neuropathy among diabetics in a rural cum costal area of Villupuram district, Tamil Nadu, Int J Res Med Sci. 2015;3(10):2567-2571.

17. Sangeetha Meena, Manikandan RC. Prevalence of peripheral neuropathy among diabetic patients in a tertiary care hospital. IAIM. 2019;6(2):28-33.

18. Lerner A, Bernabé-Ortiz A, Ticse R, et al. Type 2 diabetes and cardiac autonomic neuropathy screening using dynamic pupillometry. Diabet Med. 2015;32(11):1470–1478.

19. Fleischer, et al. Cardiovascular autonomic neuropathy is associated with macrovascular risk factors in type 2 diabetes: New technology used for routine large-scale screening adds new insight. Journal of Diabetes Science and Technology. 2014;8(4):874–880.

20. Tallat N, Savanur A, Fatima A, et al. Assessment of subclinical cardio vascular autonomic neuropathy among type II diabetic patients: A study from Karachi, Pakistan. MOJ Anat & Physiol. 2019;6(1):17-20.

21. Gupta S, Gupta N. The prevalence of cardiacauto- nomic neuropathy in type 2 diabetes mellitus. JMSCR. 2017;5(7).

22. Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. J Diabetes Investig. 2014;5:714–21.

23. Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff M, Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr. 2012;4:21.

24. Winkelmann BR, Boehm BO, Nauck M, et al. Cigarette smoking is independently associated with markers of endothelial dysfunction and hyperinsulinaemia in non-diabetic individuals with coronary artery disease. Curr Med Res Opin. 2001;17:132–141.

25. Burke A, Fitzgerald GA. Oxidative stress and smoking-induced vascular injury. Prog Cardiovasc Dis. 2003;46:79–90.

26. Benowitz NL. Cigarette smoking and cardiovascular disease: Pathophysiology and implications for treatment. Prog Cardiovasc Dis. 2003;46:91–111.

27. Anjum S, et al. To study the impact of glycemic control over cardiac autonomic neuropathy in type 1 and type 2 diabetics patients using bedside tests at a tertiary care hospital. Int J Adv Med. 2017;4(3):635-63927.

28. Zuern CS, Rizas K, Eick C, Sterz K, Gawaz M, Bauer A. Prevalence and predictors of severe autonomic failure in patients with insulin-dependent type 2 diabetes mellitus and coronary artery disease: Pilot study. J Electrocardiol. 2012;45(6):774e9.

29. Mohammad Haghighatpanah, Girish Thunga, Sarvajeethkare, Surulivel Rajan Mallaya Samy, “correlation of glycosylated hemoglobin levels with fasting and postprandial glucose in southindiantype2diabetics,” int j pharm pharm sci. 8(8):285-288.

30. MarwaK A, Tolba1, Khaled A. ElKhashab, Amira SA. Said “the effect of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risk in type 2 diabetes mellitus” int j pharm pharm sci. 9(1):254-259.

31. Pop-Busui R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress.
Diabetes Metab Res Rev. 2006; 22:257–73.

32. Vincent AM, Russell JW, Low P, Feldman EL. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev. 2004;25:612–28.